San-Antonio-BC-Symposium_prev
Recent Posts
- Sermonix Pharmaceuticals Receives U.S. Patent for Lasofoxifene as Method for Treating Aromatase-Resistant ER+ Breast Cancer in the Absence of ESR1 Mutations
- Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Paper Examining Lasofoxifene’s Preclinical Effects on Aromatase Inhibitor Resistant Non-ESR1 Mutated Breast Cancer
- Sermonix Pharmaceuticals Announces Chinese Approval of Investigational New Drug Application for Lasofoxifene
- Sermonix Pharmaceuticals Announces ‘Menopause’ Journal Publication of Article on Oral Lasofoxifene’s Effects on Vaginal Atrophy in Postmenopausal Women
- Sermonix to Host KOL Fireside Chat on Advancements in the Metastatic Breast Cancer Treatment Landscape
Archives
- July 2024
- June 2024
- April 2024
- February 2024
- January 2024
- December 2023
- November 2023
- October 2023
- September 2023
- June 2023
- May 2023
- March 2023
- February 2023
- December 2022
- November 2022
- September 2022
- August 2022
- June 2022
- April 2022
- February 2022
- December 2021
- November 2021
- June 2021
- May 2021
- April 2021
- January 2021
- December 2020
- October 2020
- September 2020
- July 2020
- June 2020
- December 2019
- September 2019
- June 2019
- May 2019
- April 2019
- March 2019
Recent Comments